The FDA originally linked contaminated heparin to some Chinese suppliers in 2008, when 80 U.S. patients died and hundreds of others experienced allergic reactions following the use of the drug. The 14 newly discovered companies joined eight other Chinese suppliers on an import alert list that allows the FDA to stop shipments at the U.S. border.
Related Articles on Supply Chain:
Jim Fitzgerald to Retire From Executive Roles at HCA Healthcare
FDA Settles For $1M With Pennsylvania Medical Device Firm Over Unapproved Devices
FDA Seeks Stricter Regulations on Hip Implants, Vaginal Mesh
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.
